glp-1-directed nmda receptor antagonism for obesity treatment Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH glp-1-directed nmda receptor antagonism for

Eli Lilly is awaiting an FDA decision on a new indication for Mounjaro covering the reduction of major adverse cardiovascular events in patients with type 2 diabetes, supported by the SURPASS CVOT trial

The main consideration during this phase is maintaining adequate nutrition despite continued appetite suppression

GLP-1 drugs prescribed for purposes other than weight loss (e.g., type 2 diabetes) remain covered under regular Part D with standard cost-sharing rules

This is particularly thanks to growth in GLP1 sales which is expected to continue

If youve looked into online GLP-1 medications for weight loss, youve probably noticed how confusing the landscape can be